SPRO 8-K 2026-11-10

Spero Therapeutics, Inc. (SPRO) 8-K dated 2026-11-10 — accession 0001193125-26-455789.

Spero Therapeutics, Inc. (SPRO) is a biotechnology company listed on NASDAQ.

Spero Therapeutics, Inc. filed a 8-K on 2026-11-10. Accession 0001193125-26-455789.

This 8-K covers: Director/officer change (Item 5.02). SEC EDGAR holds the official filing and its exhibits.

Latest reported SPRO revenue for 2025-12-31 was $66.8M. Net income was $8.6M. Revenue was up 39.2% from 2024-12-31 to 2025-12-31. SPRO currently screens at market cap $149.5M.

Not investment advice. The SPRO SEC hub lists recent forms. The stock page is the research view.